Lakefront Biotherapeutics discloses six weeks of share buybacks through July 31

Lakefront Biotherapeutics NV, formerly Galapagos, filed a series of weekly 6-K reports detailing share repurchases made under a buyback program the company said it announced on June 9, 2026.

Across six disclosed weeks, from June 22 through July 31, 2026, the company reported repurchasing a cumulative 588,012 ordinary shares for a combined 15,118,094.83 euros, executed through a discretionary mandate to an independent financial intermediary on Euronext and related trading venues (XAMS, CEUX, AQEU, TQEX).

The weekly totals were: 83,530 shares repurchased between 22 June 2026 and 26 June 2026¹ for 2,108,045.52 euros; 104,022 shares repurchased between 29 June 2026 and 03 July 2026² for 2,730,010.70 euros; 108,645 shares repurchased between 06 July 2026 and 10 July 2026³ for 2,897,722.65 euros; 98,648 shares repurchased between July 13, 2026 and July 17, 2026⁴ for 2,564,633.73 euros; 95,670 shares repurchased between July 20, 2026 and July 24, 2026⁵ for 2,431,442.30 euros; and 97,497 shares repurchased between via a discretionary mandate to an independent financial intermediary between July 27, 2026 and July 31, 2026⁶ for 2,386,239.93 euros.

Average weekly purchase prices moved from about 25.24 euros per share in late June to a high near 26.67 euros per share in the July 6-10 period, before declining to 24.48 euros per share by the week of July 27-31, 2026, according to the filings.

By the end of each reporting period, cumulative holdings of own shares rose steadily: as of market close on 26 June 2026, Lakefront holds 199,734 of its own ordinary shares¹, rising to 704,216 of its own ordinary shares⁶ as of market close on 31 July 2026. All filings were signed by Ying Deng as authorized officer.